Apimeds Pharmaceuticals US, Inc. financial data

Symbol
APUS on NYSE
Location
Matawan, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 420% %
Debt-to-equity 36% %
Return On Equity -140% %
Return On Assets -103% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12,575,983 shares
Common Stock, Shares, Outstanding 12,575,983 shares
Common Stock, Value, Issued $125,760 USD
Weighted Average Number of Shares Outstanding, Basic 12,575,983 shares 59%
Weighted Average Number of Shares Outstanding, Diluted 12,575,983 shares 59%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $619,693 USD
General and Administrative Expense $3,876,647 USD 308%
Operating Income (Loss) $5,148,124 USD -515%
Nonoperating Income (Expense) $9,354 USD
Net Income (Loss) Attributable to Parent $5,157,478 USD -436%
Earnings Per Share, Basic 0 USD/shares -250%
Earnings Per Share, Diluted 0 USD/shares -250%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,986,617 USD
Assets, Current $9,086,108 USD
Property, Plant and Equipment, Net $34,188 USD
Assets $9,250,036 USD
Liabilities, Current $1,089,384 USD
Liabilities $1,089,384 USD
Retained Earnings (Accumulated Deficit) $9,237,769 USD
Stockholders' Equity Attributable to Parent $8,160,652 USD
Liabilities and Equity $9,250,036 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $20,313 USD 92%
Net Cash Provided by (Used in) Financing Activities $267,200 USD
Common Stock, Shares Authorized 100,000,000 shares
Common Stock, Shares, Issued 12,575,983 shares
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,986,617 USD 26194%
Preferred Stock, Shares Authorized 10,000,000 shares
Additional Paid in Capital $17,272,661 USD
Share-based Payment Arrangement, Expense $178,424 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares